Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting

American Journal of the Medical Sciences

Volumn 349, Issue 5, 2015, Pages 421-424

  Ortiz, Arleen ^a   Cooper, Chad J ^a   Alvarez, Alicia ^b   Gomez, Yvette ^a   Sarosiek, Irene ^a   McCallum, Richard W ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Domperidone; Gastroparesis; Nausea and Vomiting; Prokinetic; QTc interval

Indexed keywords

17 METHYLNALTREXONE; AMITRIPTYLINE; DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; AFRICAN AMERICAN; AGED; BEDTIME DOSAGE; BODY MASS; BREAST TENDERNESS; CARDIOTOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC STOMACH PARESIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DUMPING SYNDROME; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GALACTORRHEA; HEART PALPITATION; HISPANIC; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MIDDLE AGED; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; QTC INTERVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; YOUNG ADULT; DOSE RESPONSE; DRUG MONITORING; ELECTROCARDIOGRAPHY; EPIDEMIOLOGY; ETHNOLOGY; NAUSEA; PROCEDURES; TIME; TREATMENT OUTCOME; UNITED STATES; VOMITING;

ADULT; CARDIOTOXICITY; DOMPERIDONE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; NAUSEA; RETROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME; UNITED STATES; VOMITING;

EID: 84928966718     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000439     Document Type: Conference Paper

References (21)

1. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000;102:1883-5.
2. Green LW, Ottoson JM, Garcia C, Hiatt RA. Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health 2009;30:151-74.
3. Boyce MJ, Baisley KJ, Warringon SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol 2012;73:411-21.
4. van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010;33:1003-14.
5. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19:881-8.
6. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005;26:720-3.
7. Pham CP, de Feiter PW, van der Kuy PH, et al. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother 2006; 40:1456-61.
8. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036-45.
9. Camilleri M, Parkman HP, Shafi MA, et al, Gastroenterology ACo. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37; quiz 8.
10. Alam U, Asghar O, Malik RA. Diabetic gastroparesis: Therapeutic options. Diabetes Ther 2010;1:32-43.
11. Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf 2010;5:257-62.
12. Pointe ML, Keller GA, Girolamo GD. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf 2010;5:44-53.
13. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:361-7.
14. Moskovitz JB, Hayes BD, Martinez JP, et al. Electrocardiographic implications of the prolonged QT interval. Am J Emer Med 2013;31: 866-71.
15. Sawant P, Das HS, Desai N, et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India 2004;52: 626-8.
16. Lazzerini PE, Capecchi PL, Guideri F, et al. Connective tissue disease and cardiac rhythm disorders: an overview. Autoimmun Rev 2006; 5:306-13.
17. Heer M, Müller-Duysing W, Benes I, et al. Diabetic gastroparesis: treatment with domperidone-a double-blind, placebo-controlled trial. Digestion 1983;27:214-7.
18. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989;84: 1069-75.
19. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230-4.
20. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOMUSA- 5 Study Group. Clin Ther 1998;20:438-53.
21. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1-9.